EE2: 3,4-Diaminopyridine Phosphate for AAL- The EEDAPP-ALS Trial

Authors

  • Raghav Govindarajan MD
  • Stanley Iyadurai MD
  • Alex Karenevich PhD
  • Laura Herbelin
  • Jeffrey Statland MD
  • Richard J Barohn MD

DOI:

https://doi.org/10.17161/rrnmf.v3i1.16747

Keywords:

Efficacy to Effectiveness trial, 3,4-Diaminopyhridine phosphate, Amyotrophic lateral sclerosis

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.
A painting of a family in formal dress gathered at a wedding

Downloads

Published

2022-03-11

Issue

Vol. 3 No. 1 (2022)

Section

Proposed Stuff (Funded or unfunded grant proposals)

License

Copyright (c) 2022 Raghav Govindarajan MD, Stanley Iyadurai MD, Alex Karenevich PhD, Laura Herbelin, Jeffrey Statland MD, Richard J Barohn MD

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Govindarajan, R. ., Iyadurai, S., Karenevich, A., Herbelin, L., Statland, J., & Barohn, R. (2022). EE2: 3,4-Diaminopyridine Phosphate for AAL- The EEDAPP-ALS Trial. RRNMF Neuromuscular Journal, 3(1), 34-62. https://doi.org/10.17161/rrnmf.v3i1.16747